1. Início
  2. Publicações
  3. Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause

Data de publicação:

Autores da FMUP

  • João Pedro Melo Marques Pinho Ferreira

    Autor

Participantes de fora da FMUP

  • Khan, MS
  • Butler, J
  • Anker, SD
  • Filippatos, G
  • Pocock, SJ
  • Januzzi, JL
  • Piña, IL
  • Böhm, M
  • Ponikowski, P
  • Verma, S
  • Brueckmann, M
  • Vedin, O
  • Zeller, C
  • Zannad, F
  • Packer, M

Unidades de investigação

Abstract

Background Outcomes and treatment effects of therapy may vary according to the cause of heart failure (HF). Methods and Results In this post hoc analysis of the EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction) trial, the effect of empagliflozin on cardiovascular and renal outcomes was assessed according to the cause of HF. The cause of HF was investigator reported and stratified as ischemic or nonischemic. Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% CIs. Of the 3730 patients enrolled, 1929 (51.7%) had ischemic cause. In the placebo arm, patients with ischemic cause of HF did not have a significantly higher risk of cardiovascular mortality (HR, 1.21 [95% CI, 0.90-1.63]) and hospitalization for HF (HR, 0.90 [95% CI, 0.72-1.12]) compared with nonischemic cause. Empagliflozin compared with placebo significantly reduced the risk of cardiovascular death or hospitalization for HF in patients with ischemic and nonischemic cause (HR, 0.82 [95% CI, 0.68-0.99] for ischemic and HR, 0.67 [95% CI, 0.55-0.82] for nonischemic cause; P interaction=0.15). The benefit of empagliflozin on HF hospitalization, the renal composite end point, estimated glomerular filtration slope changes, and health status scores were also consistent in both groups without treatment by cause modification. Conclusions Empagliflozin offers cardiovascular and renal benefits in patients with heart failure with reduced ejection fraction regardless of the cause of HF. Registration URL: ; Unique identifier: NCT03057977.

Dados da publicação

ISSN/ISSNe:
2047-9980, 2047-9980

Journal of the American Heart Association  Wiley-Blackwell Publishing Ltd

Tipo:
Article
Páginas:
-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Scopus: 4

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • empagliflozin; heart failure; ischemic cause

Campos de estudo

Proyectos asociados

Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022

Citar a publicação

Partilhar a publicação